Page 5 of Attachment C 
Medical Program 
The company is now developing a formal medical program for employee 
health surveillance. This program is being developed under the di- 
rection of the Director of Human Resources and a consulting physician 
who is a specialist in industrial medicine. They are arranging emer- 
gency clinical support, preemployment physicals, and serum sample 
aquisition and storage. Employees on antibiotic therapy are required 
to report to their supervisor and are excluded from working with 
recombinant DNA organisms. Production workers involved in the pro- 
duction of human growth hormone and interferon will be subject to 
fecal monitoring. 
This company has recorded no lost time accidents in its four year 
history. 
DESCRIPTION OF PAST EXPOSURES 
AND POTENTIAL HEALTH HAZARDS 
Data on exposure of employees to recombinant DNA, organisms utilized 
in fermentation processes is limited to the environmental monitoring 
previously mentioned. No quantitative results are available to docu- 
ment range or incidence of exposure. 
Other potential health hazards are radioisotopes and organic chem- 
icals such as chloroform, pyridine, formic acid, and formaldehyde. 
Proper usage, storage, and disposal requirements have been discussed 
by the company with the employees involved with these hazards. 
EVALUATION OF THE PLANT AND PROGRAMS 
Physical Containment Design 
Physical containment laboratories at the P-1 and P-3 levels, used for 
research and development of recombinant DNA techniques were toured. 
The design and operation of these laboratories were intended to be 
within the NIH guidelines. Genentech has experienced rapid growth and 
expansion with apparent priority given to advancement of the scien- 
tific and production programs. The result is a poor location of pro- 
duction areas and poor arrangement of equipment within the production 
area. On-going construction and facility modifications will possibly 
continue as the production process develops. A biosafety consultant 
is utilized by the company whenever changes are made in recombinant 
DNA containment facilities. 
Areas of the production room were under construction at the time of 
this survey. This production room is designed to meet the NIH re- 
quirements for Pl-LS level of containment with additional structural 
features that could qualify it as a P-3 laboratory. This room houses 
5 
[ 545 ] 
